Clinical trials
Diffuse Midline Glioma, H3 K27-Altered clinical trials
Below are recruiting diffuse midline glioma, h3 k27-altered clinical trials, each written for real people, not researchers. We’re tracking 5 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07589257RecruitingPhase 2
VRT106 drug combined with radiation for brain stem tumors
This trial tests whether a new drug called VRT106, given alongside radiation therapy, can help treat a serious type of brain tumor called diffuse midline glioma or DIPG. The drug is designed to work with radiation to fight the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT06357377RecruitingPhase 1
NEO100 for children with high-grade brain tumors
This trial tests a new drug called NEO100 for children with certain types of brain tumors. It is given through a needle into the tumor or nearby fluid, and the study looks at safety and the right dose.
Orange, CaliforniaAges 5–18 - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21
Hear when a new Diffuse Midline Glioma, H3 K27-Altered trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse midline glioma, h3 k27-altered?
- Yes. Clin2 currently lists 5 recruiting diffuse midline glioma, h3 k27-altered studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse midline glioma, h3 k27-altered trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse midline glioma, h3 k27-altered trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.